Event

Register Now Dr. Chris Sheldon is among the best biopharma dealmakers, and his impressive track record includes AstraZeneca/Daiichi's ~$13bn partnership of DS8201 and Dato-Dxd, AstraZeneca's $6.4b acquisition of Acerta over its Acalabrutinib, which is included in the sensation book "In Blood and Money", during his time at AstraZeneca as the head of Oncology BD. Shortly after he took the helm of the GSK's BD, he led the $2B acquisition of Bellus Health and also closed the deal with WuXi Biologics over their multiple bi- & multi-specific T cell engagers for oncology.

This event has ended. Please scroll down for the recording. Dr. Pearce started her career in 1997 at Hoffman-LaRoche, then at Merck launching therapeutics in the cardiovascular space. In 2001, Dr. Pearce joined a small CRO, Medpace, as a Clinical Project Manager. She led hundreds of global Phase 1-4 studies in a variety of therapeutic areas, including neurology, diabetes, lipid-lowering, kidney diseases, and obesity. She started the first business development team and marketing teams at Medpace in 2011. In 2013, Dr. Pearce joined Teva as VP, R&D, leading a new division dedicated to evaluating generics for repurposing. One of [...]

REGISTER HERE

REGISTER HERE

REGISTER HERE Speakers Moderator Organizers

Register Here Santi is a research scientist and business development professional with over 10 years of experience in autoimmune disease, immunology, and oncology disease areas. Santi received her training in human B cell development at the Garvan Institute of Medical Research Australia in Immunology, followed by a postdoctoral fellowship at the Children’s Cancer Institute Australia, focusing on pediatric leukemia and therapies. Her projects include testing agents' efficacy and mechanisms such as navitoclax, venetoclax, and selumetinib. Her research projects resulted in multiple publications in journals such as Blood and Journal of Immunology and national/international awards. Sponsored by GemPharmatech GemPharmatech, [...]